Physiologically based pharmacokinetic models for everolimus and sorafenib in mice

Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.

Laurence T. Baxter, Hui Zhu, Daniel G. Mackensen · PubMed · 1994 · 282 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

Chetan Lathia, John Lettieri, Frank Cihon et al. · Cancer Chemotherapy and Pharmacology · 2005 · 208 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +10

Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness

Gaber Komar, Saila Kauhanen, Kaisa Liukko et al. · Clinical Cancer Research · 2009 · 175 citations

Medicine, Nuclear Medicine, Oncology +17

The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

Sagar Agarwal, Ramola Sane, John R. Ohlfest et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 160 citations · Full text

Medicine, Oncology, Pharmacology +13

Population pharmacokinetic analysis of sorafenib in patients with solid tumours

Lokesh Jain, Sukyung Woo, Erin R. Gardner et al. · British Journal of Clinical Pharmacology · 2011 · 144 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14